Avanos Medical (NYSE:AVNS) Upgraded at StockNews.com

StockNews.com upgraded shares of Avanos Medical (NYSE:AVNS) from a hold rating to a buy rating in a research report released on Wednesday morning.

Avanos Medical Price Performance

Shares of NYSE:AVNS opened at $14.67 on Wednesday. Avanos Medical has a fifty-two week low of $14.25 and a fifty-two week high of $25.36. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The company has a market cap of $675.05 million, a PE ratio of 43.16 and a beta of 1.17. The firm has a 50-day simple moving average of $15.83 and a 200 day simple moving average of $18.72.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The firm had revenue of $179.60 million during the quarter, compared to analysts’ expectations of $177.23 million. On average, sell-side analysts anticipate that Avanos Medical will post 1.32 EPS for the current year.

Insider Transactions at Avanos Medical

In related news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total transaction of $106,750.00. Following the completion of the sale, the senior vice president now directly owns 82,047 shares of the company’s stock, valued at $1,251,216.75. This represents a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.94% of the company’s stock.

Institutional Trading of Avanos Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in shares of Avanos Medical in the 3rd quarter valued at approximately $42,000. Quantbot Technologies LP acquired a new position in Avanos Medical in the 4th quarter valued at approximately $64,000. KBC Group NV increased its stake in Avanos Medical by 63.0% in the 3rd quarter. KBC Group NV now owns 2,833 shares of the company’s stock valued at $68,000 after buying an additional 1,095 shares during the period. State of Wyoming increased its stake in Avanos Medical by 132.0% in the 4th quarter. State of Wyoming now owns 5,137 shares of the company’s stock valued at $82,000 after buying an additional 2,923 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Avanos Medical by 493.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company’s stock valued at $129,000 after buying an additional 6,714 shares during the period. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.